Clinical studies on the therapeutic targeting of TGF-β in the context of renal disease have not focused on PWH as a treatment group, and further large-scale investigations are required to determine whether TGF-β inhibition has therapeutic potential in HIV-associated nephropathy. This evidence concerns the gene TGFB1 and Nephropathy.